VEGFA and head and neck squamous cell carcinoma: Dual targeting of EGFR and VEGF pathways, however, offers a potential opportunity for a subgroup of patients unable to receive a cisplatin-based first-line therapy for R/M HNSCC [22,32,42] and represents a potential strategy to improve efficiency, as demonstrated by the studies by Cohen et al. [42] and Argiris et al. [32].